InMed Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über InMed Pharmaceuticals Inc Unternehmen

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

InMed Pharmaceuticals Inc Informationen



BörsenkürzelINM

Name des UnternehmensInMed Pharmaceuticals Inc

IPO-datumJun 21, 2001

CEOAdams (Eric A)

Anzahl der mitarbeiter- -

WertpapierartOrdinary Share

GeschäftsjahresendeJun 21

Addresse1445-885 West Georgia St.

StadtVANCOUVER

BörseNASDAQ OMX - NASDAQ BASIC

LandCanada

PostleitzahlV6C 3E8

Telefon16046697207

Websitehttps://www.inmedpharma.com/

BörsenkürzelINM

IPO-datumJun 21, 2001

CEOAdams (Eric A)

Führungskräfte von InMed Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Andrew Harold Hull

Independent Chairman of the Board

1.91K

--

Dr. Eric Chih-Hsien Hsu, Ph.D.

Senior Vice President - Preclinical Research and Development

2.00

--

Mr. Michael Henry Woudenberg

Chief Operating Officer

1.00

--

Mr. Eric A. Adams

President, Chief Executive Officer, Director

--

Mr. Colin Clancy

Vice President, Investor Relations and Corporate Communications

--

Mr. Bryan T. Baldasare

Independent Director

--

Ms. Nicole Lemerond

Independent Director

--

-100.00%

Ms. N. Netta (Neeta) Jagpal, CPA

Chief Financial Officer

--

Mr. Neil A. Klompas, CPA

Independent Director

--

Mr. John Bathery

Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Andrew Harold Hull

Independent Chairman of the Board

1.91K

--

Dr. Eric Chih-Hsien Hsu, Ph.D.

Senior Vice President - Preclinical Research and Development

2.00

--

Mr. Michael Henry Woudenberg

Chief Operating Officer

1.00

--

Mr. Eric A. Adams

President, Chief Executive Officer, Director

--

Mr. Colin Clancy

Vice President, Investor Relations and Corporate Communications

--

Mr. Bryan T. Baldasare

Independent Director

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, May 14

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Sabby Management, LLC

6.08%

Yorkville Advisors Global, LP.

2.43%

Susquehanna International Group, LLP

0.38%

UBS Financial Services, Inc.

0.24%

Private Wealth Management Group, LLC

0.15%

Andere

90.71%

Aktionäre

Anteil

Sabby Management, LLC

6.08%

Yorkville Advisors Global, LP.

2.43%

Susquehanna International Group, LLP

0.38%

UBS Financial Services, Inc.

0.24%

Private Wealth Management Group, LLC

0.15%

Andere

90.71%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor/Hedge Fund

8.51%

Investment Advisor

0.78%

Research Firm

0.37%

Individual Investor

0.12%

Andere

90.22%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

31

320.11K

9.66%

-43.64K

2025Q4

29

434.23K

15.48%

+143.86K

2025Q3

30

135.23K

4.82%

+48.77K

2025Q2

37

127.03K

6.34%

+18.71K

2025Q1

34

127.03K

10.75%

+32.44K

2024Q4

33

169.52K

14.04%

+76.54K

2024Q3

35

65.17K

63.92%

+11.73K

2024Q2

34

30.10K

7.60%

-6.51K

2024Q1

33

42.40K

13.49%

-1.13K

2023Q4

31

40.41K

15.37%

-91.29K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Sabby Management, LLC

201.63K

6.91%

-18.36K

-8.35%

Dec 31, 2025

Yorkville Advisors Global, LP.

80.37K

2.75%

+80.37K

--

Dec 13, 2024

Susquehanna International Group, LLP

12.75K

0.44%

+12.75K

--

Dec 31, 2025

UBS Financial Services, Inc.

377.00

0.01%

+377.00

--

Dec 31, 2025

Adams (Eric Ashley)

2.20K

0.08%

--

Oct 22, 2025

Hull (Andrew Harold)

1.91K

0.07%

--

Oct 22, 2025

SBI Securities Co., Ltd.

300.00

0.01%

--

Dec 31, 2025

Banque Cantonale Vaudoise

6.00

0%

--

Dec 31, 2025

Hsu (Eric Chih-Hsien)

2.00

0%

--

Oct 22, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

AdvisorShares Pure Cannabis ETF

0%

AdvisorShares Pure Cannabis ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Nov 12, 2024

Merger

20→1

Nov 12, 2024

Merger

20→1

Nov 12, 2024

Merger

20→1

Nov 12, 2024

Merger

20→1

Aug 26, 2022

Merger

25→1

Aug 26, 2022

Merger

25→1

Datum

Ex-Dividendentag

Art

Verhältnis

Nov 12, 2024

Merger

20→1

Nov 12, 2024

Merger

20→1

Nov 12, 2024

Merger

20→1

Nov 12, 2024

Merger

20→1

Aug 26, 2022

Merger

25→1

Aug 26, 2022

Merger

25→1

Aug 26, 2022

Merger

25→1

Aug 26, 2022

Merger

25→1